IP Library Granted Patent US 9,358,278
Granted Patent B2
US 9,358,278 · App. 12/321,464 · Granted Jun 7, 2016

Capsular polysaccharide solubilisation and combination vaccines

Inventor: Paolo Costantino (Siena, IT)
Assignee: Novartis AG
A61K39/095A23J1/04A23J1/205A61K38/00A61K2039/545A61K2039/55505A61K2039/6037C07H15/04C09F1/00Y10S424/831
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,358,278
App. No.
12/321,464
Granted
Jun 7, 2016
Kind
B2
Abstract

Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.

Claims (13)

1. A process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitating the polysaccharide using one or more cationic detergents without an inert porous support, followed by (b) solubilising the precipitated polysaccharide using an alcohol, wherein the bacterial capsular polysaccharide is from Neisseria meningitidis, Haemophilus influenzae or Streptococcus pneumoniae , wherein the process does not comprise precipitating the polysaccharide using one or more cationic detergents on an inert porous support.

2. A process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitating the polysaccharide using one or more cationic detergents, followed by (b) solubilising the precipitated polysaccharide using an alcohol, wherein the alcohol comprises ethanol and the ethanol has a final concentration of between 65% and 95%.

3. A process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitating the polysaccharide using one or more cationic detergents, followed by (b) solubilising the precipitated polysaccharide using pure ethanol or an ethanol:water mixture, wherein the ethanol:water mixture does not comprise a salt.

4. The process of any one of claims 1 to 2 , wherein the cationic detergent(s) comprise a cetyltrimethylammonium salt, a tetrabutylammonium salt, a myristyltrimethylammonium salt and/or hexadimethrine bromide.

5. The process of any one of claims 1 to 3 , wherein the polysaccharide obtained in step (b) is then precipitated.

6. The process of claim 5 , wherein precipitation is by addition of calcium or sodium salts.

7. The process of any one of claim 1 , 2 , or 3 , further comprising the step of conjugation to a carrier protein.

8. The process of claim 7 , wherein the carrier protein is a diphtheria toxoid or tetanus toxoid.

9. The process of claim 7 , wherein the saccharide is activated prior to conjugation.

10. The process of claim 9 , wherein activation involves a cyanylating reagent.

11. The process of claim 9 , wherein conjugation is with a linker.

12. The process of claim 7 , wherein, after conjugation, free and conjugated saccharides are separated.

13. The process of claim 12 , wherein separation uses hydrophobic chromatography, tangential ultrafiltration, or diafiltration.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2016
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 038903/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2011
From: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
To: NOVARTIS PHARMA AG
Reel/Frame 026279/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2011
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 026279/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2011
From: COSTANTINO, PAOLO
To: CHIRON S.R.L.
Reel/Frame 026268/0112 →
CHANGE OF NAME Recorded May 12, 2011
From: CHIRON S.R.L.
To: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
Reel/Frame 026268/0616 →
Priority Claims (1)
GB 0115176.0 · Jun 20, 2001 · national
Continuity (2)
Division 10481457
Related Publication 20090182129A1 · Jul 16, 2009